Tocagen Cultura de la Empresa

Mr. Mark G. Foletta, CPA, has been Chief Financial Officer and Executive Vice President of Tocagen Inc. since February 2017. Mr. Foletta has been Consultant of Biocept, Inc. since September 2016. He is a Co-Owner of Foletta Family Trust. He serves as the President and Treasurer of Amylin Ohio LLC. He served as the Interim Chief Financial Officer of Biocept, Inc. from August 30, 2015 to July 27, 2016. He is a seasoned financial executive with over 30 years of corporate experience. He served as an Advisor to Chief Executive Officer and Board at Islet Sciences, Inc. from July 15, 2013 to July 30, 2013. He served as a Senior Vice President of Finance at Amylin Pharmaceuticals Inc. (also known as, Amylin Pharmaceuticals, LLC) from March 2006 to October 2012 and also served as its Chief Financial Officer from March 2006 to October 2012 and Principal Accounting Officer until October 2012. He served as a Vice President of Finance at Amylin Pharmaceuticals Inc. from March 2000 to March 2006. He served as Principal of Triton Acquisition Corp (Triton Group Management, Inc). from 1997 to 2000. From 1986 to 1997, Mr. Foletta held a number of management positions with InterMark Inc. and Triton Group Ltd. He served as the Chief Financial Officer and Senior Vice President of Triton Group, Ltd. since June 1994 and served as its Corporate Secretary since 1992. From 1982 to 1986, he was with Ernst & Young and served as its Audit Manager. He served as a Vice President and Corporate Controller of Triton Group Ltd. and InterMark, Inc. from 1991 to June 1994. He served as a Vice President at Pharmatek Laboratories, Inc. He has been a Director of ViaCyte, Inc. since December 19, 2013. He serves as Lead Independent Director at DexCom, Inc. He has been an Independent Board member of DexCom, Inc. since November 19, 2014. He has been an Independent Director of Regulus Therapeutics Inc. since January 2013 and AMN Healthcare Services Inc. since December 10, 2012. He serves as a Director of Mission West Properties and Pharmatek Laboratories, Inc. He served as a Director of Ambit Biosciences Corporation from January 27, 2014 to November 10, 2014. He served as an Independent Director of Anadys Pharmaceuticals Inc from September 6, 2005 to November 23, 2011. He served as a Director of Triton Group Ltd. since February 1996. He a member of the Corporate Directors Forum. Mr. Foletta holds a B.A. in Business Economics from the University of California, Santa Barbara in 1982. He is a Certified Public Accountant accreditation in 1985. He is a member of the Financial Executives Institute.

Dr. Harry E. Gruber, M.D. has been President of Science & Innovation at Tocagen Inc. since October 27, 2017. Dr. Gruber served as the President of Research and Development of Tocagen Inc. since November 2, 2016 and also served as its Chief Executive Officer and President until November 2, 2016. Dr. Gruber Co-founded Tocagen Inc., in 2007 a company dedicated to the development and commercialization of breakthrough treatments for cancer using advanced gene transfer technology. He was a founder and served as Chairman, Chief Executive Officer and President of Kintera, Inc. from February 8, 2000 to February 9, 2007. Previously, Dr. Gruber was a founder and/or inventor of the underlying technology for the following public companies, which achieved a combined value over $7 billion: Viagene, Inc. (a gene therapy company acquired by Novartis Pharmaceuticals), Gensia Inc. (acquired by Teva Pharmaceutical Industries, Ltd.), Intervu Inc. (acquired by Akamai Technologies, Inc.), Kintera Inc. (acquired by Blackbaud) and Metabasis, Inc. (acquired by Ligand Pharmaceuticals). He served as the Chairman of Tocagen Inc. and serves as its Director. He served as Director of Kintera Inc. since February 8, 2000 He is the author of over 100 original scientific articles and an inventor on over 33 issued and numerous pending patents. Dr. Gruber holds a BA and a MD from the University of Pennsylvania and trained in Internal Medicine, Biochemical Genetics and Rheumatology/Immunology at the University of California, San Diego, where he subsequently joined the medical school faculty until founding Gensia Inc.

Dr. Douglas J. Jolly, also known as Doug, Ph.D., Co-founded Tocagen, Inc., in 2007 and has been its Executive Vice President of Research and Pharmaceutical Development since December 2007. Dr. Jolly served as the President and Chief Operating Officer of Advantagene, Inc. Dr. Jolly is responsible for numerous clinical trials. He served as Vice President for Scientific Affairs of Chiron Corporation's Center for Gene Therapy. He has advised the US National Institutes of Health and the FDA on scientific strategy and regulatory issues. He has an extensive experience in moving new vector technologies through the regulatory processes required by federal agencies including the FDA and National Institutes of Health (NIH). Dr. Jolly served as the Chief Executive Officer- BIOMEDICA Inc. of Oxford BioMedica PLC. He co-founded Viagene Inc. and served as its Vice President of Research. He is an internationally recognized expert in the field of gene therapy and its industrial application. For most of the last twenty years, Dr. Jolly is a senior biotechnology executive, involved in translating gene-based products from research through clinical development at the following companies: Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., and Advantagene, Inc. He served as a Director of Oxford BioMedica PLC. from May 2001 to March 2, 2004. He is a leading figure in gene technology in the USA. He has published over 100 scientific articles. He is an Inventor on over 45 US and European issued patents. He is highly respected as a pioneer in the clinical application and commercialization processes for gene therapy product candidates. He serves as Chairman of the Industrial Liaison Committee of the American Society of Gene Therapy (ASGT). Dr. Jolly pursued his academic career in Biophysics and Molecular Biology at the Weizmann Institute, Harvard Medical School, Scripps Clinic, the University of California, San Diego and The French National Institute for Health and Medical Research (INSERM) in Paris, France. Dr. Jolly received his education in Scotland and holds a PhD in Biochemistry from the University of Glasgow.

Dr. Asha Das, M.D. has been Chief Medical Officer and Senior Vice President at Tocagen Inc., since March 2017. Dr. Das served as Acting Chief Medical Officer and Vice President of Clinical Development & Medical Affairs at Tocagen Inc., from May 2016 to March 2017 and from April 2015 to March 2017 respectively. From April 2008 to April 2015, Dr. Das served in positions of increasing responsibility at Genentech Inc., a biotechnology company and member of the Roche Group, initially as Associate Medical Director and ultimately as Group Medical Director. From 2005 to 2008, she served as Associate Medical Director at Eisai Inc., a pharmaceutical company. Prior to that, she was Head of the Neuro-Oncology Program at Cedars-Sinai Medical Center. She is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology by the United Council for Neurologic Subspecialties and previously served as a clinical fellow in neuro-oncology at Massachusetts General Hospital. Dr. Das has completed a residency in neurology at Cornell Medical Center and has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. Dr. Das obtained her M.D. and Bachelor's degree from Cornell University.

Sophie Visonneau serves as the Vice President Clinical Operations of Tocagen Inc.. Sophie started at Tocagen Inc. in Mar of 2018. Sophie currently resides in the Greater San Diego Area.

Thomas Darcy serves as the Director, Retired Co-Founder, Executive Vice President and Chief Financial Officer of Tocagen Inc.. Thomas started at Tocagen Inc. in July of 2007. Thomas currently resides in the Greater San Diego Area.

Carlos Ibanez serves as the Vice President of Prod Dev and Manufacturing of Tocagen Inc.. Carlos started at Tocagen Inc. in March of 2015. Carlos currently resides in the Greater San Diego Area.

John Wood serves as the Vice President, RA & QA of Tocagen Inc.. John started at Tocagen Inc. in January of 2016. John currently resides in the Greater San Diego Area.